Equine/Camelid Stem Cells

Overview

Akira Horse/Camel MSCs are UCT-WJ-MSCs formulated for equine and camelid applications — the largest and most high-value segment of veterinary regenerative medicine. Performance horses (racehorses, showjumpers, polo horses) and racing camels represent high-value applications where the economics of regenerative medicine are most compelling. UCT-derived MSCs outperform the standard adipose or bone marrow sources typically used in equine practice, providing superior anti-inflammatory potency and tissue regeneration capacity without invasive collection procedures.

Related: Stem Cells Overview • Pet Stem Cells

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

How Horse/Camel MSCs Work

Tendon and ligament injuries, joint degeneration, and chronic airway inflammation in performance horses and racing camels share a common limitation of the standard-of-care regenerative approach: autologous bone marrow- or adipose-derived MSCs require an invasive harvest procedure from the animal itself, a delay for cell expansion, and are constrained by the donor animal's own age- and health-related decline in MSC potency. UCT-WJ-MSCs are collected from donor umbilical cord tissue at birth (a non-invasive, ethically simple collection with no impact on the donor animal), expanded, and banked as an allogeneic, off-the-shelf product — allowing immediate treatment at the time of injury rather than after a harvest-and-culture delay. Allogeneic Wharton's Jelly-derived MSCs share the low immunogenicity (low MHC-II expression) and equivalent or superior paracrine potency (anti-inflammatory, proangiogenic, tenogenic) reported for allogeneic MSC use in horses, positioning UCT-WJ-MSCs as a practical substitute for autologous bone marrow/adipose MSCs across the same intralesional, intra-articular, and intrabronchial delivery routes already used clinically in equine practice.

Tendon & Ligament Repair: Intralesional MSC delivery under ultrasound guidance is the established benchmark for equine tendonitis and suspensory ligament injury, with paracrine TGF-β, VEGF, and HGF cargo supporting collagen fiber realignment and reducing re-injury rates versus conservative management.

Joint Homeostasis: PGE2 secretion, alongside other MSC-secreted immunomodulatory mediators, suppresses synovial macrophage activation and catabolic cytokine production (IL-1β, TNF-α), supporting cartilage matrix preservation in osteoarthritis and joint degeneration — a mechanism confirmed in adipose-derived MSC effects on chondrocytes and synoviocytes from osteoarthritis patients^[1] — paralleling mechanistic and outcome data from human knee OA MSC trials.

Systemic Immunomodulation: IV-administered MSCs shift circulating cytokine balance from pro-inflammatory (IL-1β) toward anti-inflammatory (IL-10), relevant to the systemic inflammatory component of equine asthma and recurrent airway obstruction.^[2]

Airway Inflammation Resolution: Intrabronchial MSC delivery has been investigated head-to-head against oral dexamethasone in severe equine asthma, producing modest short-term cytokine (IL-17, IL-1β, IL-4, TNFα) reduction and improved clinical signs at one year, though non-inferiority to dexamethasone was not established in that trial. UCT-derived MSCs provide the same anti-inflammatory (PGE2, IL-10, TGF-β) and angiogenic (VEGF, HGF) paracrine profile validated in these studies, without invasive bone marrow or adipose harvest.

Key Biomarkers & Characterization (MSC)

Surface marker expression is confirmed by immunophenotyping of equine bone-marrow- and adipose-derived MSCs, the same identity panel used to characterize Akira's UCT-WJ-MSCs for equine and camelid use.^[3]

Potential Applications

• Tendonitis & Suspensory Ligament Injuries — biologic augmentation of tendon healing
• Osteoarthritis & Joint Degeneration — intra-articular regenerative injection
• Wound Healing — soft tissue injury recovery
• Performance Optimization — reducing oxidative stress and tissue fatigue
• Respiratory Conditions — equine asthma, recurrent airway obstruction

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Clinical Evidence (MSC)

Horse/Camel Neural Stem Cells

Akira Horse/Camel Neural Stem Cells represent a pioneering product in equine neurology. Wobbler syndrome and EPM sequelae are documented to leave residual neurologic deficits even after standard management (surgical decompression for cervical stenotic myelopathy,^[6] antiprotozoal drugs for EPM^[7]), which addresses the underlying structural or infectious cause but does not repair neural tissue already damaged; traumatic spinal cord injury, head trauma, and hindlimb ataxia share this same gap, though camelid-specific data is limited. Neural stem cells differentiated from UCT-WJ-MSCs are intended to supply a neurotrophic and remyelinating paracrine cargo (BDNF, GDNF, NT-3, CNTF) directly to injured spinal cord or brain tissue via intrathecal or local delivery, mirroring the mechanism explored in human Wharton's Jelly MSC intrathecal spinal cord injury trials.^{[8] [9] [10] [11] [12]} As an allogeneic, banked, immune-privileged product, it avoids the practical barrier of sourcing autologous neural progenitors from an already-compromised animal, and intrathecal/local delivery concentrates the neurotrophic cargo directly in the CSF/lesion compartment rather than relying on systemic blood-brain-barrier crossing.

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

Neurotrophic Support & Axonal Regeneration: BDNF and NT-3 cargo activate TrkB/TrkC signaling in surviving neurons and axons, supporting axonal sprouting across the site of compressive or traumatic spinal cord injury — consistent with the enhanced neurogenic secretome profile of UC-MSC-derived neurospheres^[13] and emerging extracellular-vesicle-based approaches to spinal cord injury treatment.^[14]

Remyelination: CNTF and GDNF cargo support oligodendrocyte survival and differentiation, promoting remyelination of demyelinated white matter tracts seen in Wobbler syndrome and EPM-associated spinal cord lesions.

Neuroinflammation Resolution: miR-146a and IL-10-associated secretory cargo suppress microglial/macrophage-driven neuroinflammation at the injury site, limiting secondary injury expansion in acute head trauma and spinal cord injury.

Neural Marker Expression: Nestin, Sox2, and beta-III-tubulin upregulation confirm neural-lineage commitment relative to undifferentiated MSCs, indicating a cargo enriched for CNS-relevant neurotrophic and structural signals.

Key Biomarkers & Characterization (Neural)

Potential Neurological Applications

• Spinal Cord Injury (Wobbler Syndrome, EPM Sequelae): neural repair and axonal support.
• Head Trauma: lesion recovery and neuroprotection.
• Hindlimb Ataxia: motor circuit support.

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Clinical Evidence (Neural)

No large-animal RCTs yet exist for Wobbler syndrome or EPM sequelae; evidence below is drawn from preclinical spinal cord injury models and neural stem/exosome studies pending dedicated equine/camelid trials.